Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,772.00 | 1.00 | -0.01% |
CAC 40 | 7,662.59 | 3.32 | -0.04% |
DAX 40 | 23,673.29 | 236.32 | -0.99% |
Dow JONES (US) | 44,575.47 | 480.70 | 1.09% |
FTSE 100 | 8,785.33 | 24.37 | 0.28% |
HKSE | 24,072.28 | 211.87 | -0.87% |
NASDAQ | 20,240.17 | 129.57 | -0.64% |
Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
NZX 50 Index | 12,734.53 | 131.71 | 1.05% |
S&P 500 | 6,206.32 | 1.37 | 0.02% |
S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
SSE Composite Index | 3,444.43 | 20.20 | 0.59% |